Patent ID: 6333317
Filing Date: 2001-12-25
Classification: A61K

Abstract:
A method of inhibiting expression, production, or formation of amyloid precursor protein (APP) in a subject comprising administering to the subject an effective amount of an agent wherein said agent is a lipophilic hormone, anaalog of a lipophilic hormone, a substance that is a ligand, an agonist, or an antagonist of a receptor that is coupled to a lipophilic hormone, and a pharmaceutically acceptable carrier or diluent, in which the effective amount is at least about 0.20 mg/kg body weight, and wherein said agent is selected from the group consisting of androsterone; 4-androstane-3,17-dione; danazol; dehydroepiandrosterone sulfate sodium; estradiol; 17.beta.-estradiol; 17.beta.-estradiol; HBC complex; estrone; fluoxymesterone; methandrostenolone; nandrolone decanoate; oxandrolone; oxymetholone; pregnenolone sulfate sodium; progesterone; progesterone; HBC complex; stanolone; testosterone; HBC complex; testosterone, 17.beta.-cypionate; testosterone, 17.beta.-decanoate; testosterone, 17.beta.-heptanoate; testosterone, 17.beta.-isocapronate; testosterone, 17.alpha.-methyl-; testosterone, 17.beta.-propianate; methoxychlor; and gonadotropin.